|Bid||15.82 x 1300|
|Ask||15.83 x 1300|
|Day's Range||15.74 - 16.62|
|52 Week Range||15.74 - 25.77|
|Beta (5Y Monthly)||1.06|
|PE Ratio (TTM)||77.27|
|Earnings Date||Feb. 08, 2022 - Feb. 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.77|
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ALAMEDA, Calif., November 20, 2021--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from the first planned analysis of COSMIC-312, the ongoing phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma (HCC). The data are being presented at 7:00 p.m. SGT (6:00 a.m. EST, 3:00 a.m. PST) on Saturday, November 20 in the Virtual Plenary Session during the European S
Time and again, Wall Street has shown investors the power of patience. Over the past 71 years, the broad-based S&P 500 has undergone 38 double-digit percentage corrections. Despite the regularity of these moves lower, every crash and correction throughout this period was eventually erased by a bull market rally.